Pierre Fabre Laboratories in den Nachrichten
Globale Pharmazeutika, Dermokosmetika, französischer Marktführer
Tamtam hat 18 aktuelle Artikel über Pierre Fabre Laboratories gefunden.
- Ali Zeaiter Brings 20 Years of Oncology Experience to Pierre Fabre
- Pierre Fabre, Atara resubmit Ebvallo BLA after two FDA CRLs
- Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease to the FDA
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
- Laboratoires Pierre Fabre appoints Zombré CEO of U.S. Dermocosmetics operations in Secaucus
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO of U.S. Dermocosmetics Business, Signaling Next Phase of Growth
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO of U.S. Dermocosmetics Business, Signaling Next Phase of Growth
- Pierre Fabre appoints Venaïg Solinhac as CEO of Dermo-Cosmetics and Personal Care
- Pierre Fabre Invest increases its stake in MiYé to 38 %
- Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color
- Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metast
- Oxurion: Pierre Fabre Adopts Exagis Platform from its Subsidiary Axiodis
- Oxurion : Pierre Fabre adopte la plateforme Exagis de sa filiale Axiodis
- Major market validation: Pierre Fabre Laboratories uses Oxurion's Exagis Platform
- The Eau Thermale Avène brand is pushing Laboratoires Pierre Fabre to accelerate its production – Interview
- Pierre Fabre Laboratories Receives CHMP Positive Opinion For BRAFTOVI Combination In First Line BRAF Mutant Metastatic Colorectal Cancer
- Pierre Fabre plans to double production capacity at Avène plant in France
- Pierre Fabre : 50 millions d’euros pour doubler la production de l’usine d’Avène
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Pierre Fabre Laboratories?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden